Dynavax Q3 Net Income Jumps 53% on Strong HEPLISAV-B Sales

TL;DR

**Dynavax's Q3 profit surge is a strong buy signal, despite the nine-month loss being a one-off debt hit.**

AI Summary

Dynavax Technologies Corporation reported a significant increase in net income for the three months ended September 30, 2025, reaching $26.927 million, up from $17.594 million in the same period of 2024, representing a 53.05% increase. This was driven by a 17.06% rise in total revenues to $94.876 million from $80.630 million year-over-year. Product revenue, primarily from HEPLISAV-B, increased by 13.38% to $89.954 million from $79.345 million. However, for the nine months ended September 30, 2025, the company reported a net loss of $50.451 million, a stark contrast to the net income of $20.259 million in the prior year, largely due to an $82.095 million loss on debt extinguishment and a $10.970 million bad debt expense. Despite the nine-month loss, operating income for the quarter more than doubled to $21.271 million from $10.082 million. Cash and cash equivalents significantly increased to $160.247 million as of September 30, 2025, from $95.883 million at December 31, 2024. The company also repurchased 10,477 shares of common stock for $100.635 million during the nine-month period.

Why It Matters

Dynavax's strong quarterly performance, particularly the 53% surge in net income and robust HEPLISAV-B sales, signals positive commercial momentum for investors. This growth, despite a significant nine-month net loss driven by one-time debt extinguishment costs, suggests underlying operational strength. For employees, continued revenue growth and pipeline advancements in shingles and plague vaccines could mean job security and future opportunities. Customers benefit from the continued availability and potential expansion of effective vaccines. In the competitive landscape, Dynavax's CpG 1018 adjuvant platform positions it as a key player in vaccine innovation, potentially challenging larger pharmaceutical companies in specific therapeutic areas.

Risk Assessment

Risk Level: medium — The company reported a significant net loss of $50.451 million for the nine months ended September 30, 2025, primarily due to an $82.095 million loss on debt extinguishment and a $10.970 million bad debt expense. While the quarterly performance was strong, these substantial one-time charges indicate potential volatility and financial management risks.

Analyst Insight

Investors should consider the strong quarterly net income and product revenue growth as a positive indicator of Dynavax's core business. However, they must factor in the significant nine-month net loss driven by one-time debt extinguishment and bad debt expenses, which suggests a need for careful monitoring of future financial stability and debt management strategies.

Financial Highlights

debt To Equity

0.77

revenue

$94,876,000

operating Margin

22.42%

total Assets

$946,506,000

total Debt

$325,169,000

net Income

$26,927,000

eps

N/A

gross Margin

84.59%

cash Position

$160,247,000

revenue Growth

+17.06%

Revenue Breakdown

Key Numbers

• $26.927M — Net Income (Q3 2025) (Increased 53.05% from $17.594M in Q3 2024)
• $94.876M — Total Revenues (Q3 2025) (Increased 17.06% from $80.630M in Q3 2024)
• $89.954M — Product Revenue (Q3 2025) (Increased 13.38% from $79.345M in Q3 2024)
• ($50.451M) — Net Loss (YTD Q3 2025) (Shift from $20.259M net income in YTD Q3 2024)
• $82.095M — Loss on Debt Extinguishment (YTD Q3 2025) (Primary driver of YTD net loss)
• $10.970M — Bad Debt Expense (YTD Q3 2025) (Contributed to YTD net loss)
• $160.247M — Cash and Cash Equivalents (Sept 30, 2025) (Increased from $95.883M at Dec 31, 2024)
• 117,424,968 — Shares Outstanding (Nov 3, 2025) (Reflects share repurchase activity)
• $100.635M — Common Stock Repurchase (YTD Q3 2025) (Reduced outstanding shares)

Key Players & Entities

• Dynavax Technologies Corporation (company) — registrant
• HEPLISAV-B (company) — first marketed product
• CpG 1018 adjuvant (company) — adjuvant used in HEPLISAV-B
• U.S. Department of Defense (company) — collaborator for plague vaccine
• Vaxart, Inc. (company) — strategic partnership
• SEC (regulator) — Securities and Exchange Commission
• $26.927 million (dollar_amount) — Net income for Q3 2025
• $17.594 million (dollar_amount) — Net income for Q3 2024
• $50.451 million (dollar_amount) — Net loss for nine months ended September 30, 2025
• $82.095 million (dollar_amount) — Loss on debt extinguishment for nine months ended September 30, 2025

FAQ

Risk Factors

• Debt Extinguishment and Bad Debt Expenses [high — financial]: The nine-month period ended September 30, 2025, incurred a significant $82.095 million loss on debt extinguishment and a $10.970 million bad debt expense. These one-time or unusual charges heavily impacted the year-to-date net income, turning it into a substantial loss.
• Reliance on HEPLISAV-B [medium — operational]: Product revenue, which constitutes the vast majority of total revenue, is heavily reliant on HEPLISAV-B. While this product is performing well with a 13.38% increase in Q3 2025 product revenue, any disruption to its sales or production could significantly impact the company's financial performance.
• Market Adoption and Competition [medium — market]: Continued success depends on the market adoption of HEPLISAV-B and the company's ability to compete effectively. While Q3 revenue growth is positive, sustained growth requires ongoing market penetration and differentiation from competitors.
• Regulatory Compliance [medium — regulatory]: As a biotechnology company, Dynavax is subject to stringent regulatory oversight from bodies like the FDA. Any delays in approvals, changes in regulations, or compliance issues could adversely affect product development and commercialization.
• Inventory Management [low — financial]: Inventories increased to $73.288 million from $70.054 million. Effective inventory management is crucial to avoid obsolescence and manage working capital, especially given the product-specific nature of the business.

Industry Context

Dynavax operates in the biotechnology and pharmaceutical sector, focusing on vaccine development and commercialization. The industry is characterized by high R&D costs, long development cycles, stringent regulatory hurdles, and significant market potential for successful therapies. Key trends include the increasing demand for preventative vaccines and advancements in immunology.

Regulatory Implications

As a biopharmaceutical company, Dynavax is subject to rigorous regulatory scrutiny from agencies like the FDA. Compliance with manufacturing standards, clinical trial protocols, and post-market surveillance is paramount. Any adverse regulatory actions or delays in approvals could significantly impact product timelines and market access.

What Investors Should Do

1. Monitor HEPLISAV-B sales trajectory and market penetration.
2. Analyze the impact of the debt extinguishment and bad debt expenses.
3. Evaluate the company's cash burn rate and future funding needs.
4. Assess the implications of the share repurchase program.

Key Dates

• 2025-09-30: End of Q3 2025 — Reported strong quarterly net income of $26.927 million and increased cash position to $160.247 million.
• 2025-12-31: End of Fiscal Year 2024 — Cash and cash equivalents were $95.883 million, providing a baseline for the significant increase observed in 2025.
• 2025-11-03: Common Stock Outstanding Update — 117,424,968 shares outstanding, reflecting the impact of the $100.635 million common stock repurchase program year-to-date.

Glossary

HEPLISAV-B

A vaccine for the prevention of hepatitis B infection. (It is the primary product driving Dynavax's product revenue, and its sales performance is critical to the company's financial results.)

Loss on Debt Extinguishment

A loss recognized when a company repays or retires its debt before its scheduled maturity date, often involving fees or penalties. (A significant $82.095 million loss from this item heavily impacted Dynavax's nine-month net income for 2025.)

Bad Debt Expense

An expense recognized for accounts receivable that are deemed uncollectible. (Contributed $10.970 million to the net loss for the nine months ended September 30, 2025.)

Convertible Notes

Debt securities that can be converted into a predetermined amount of the issuer's equity. (Dynavax has significant amounts of convertible notes, both current and long-term, which represent a substantial portion of its liabilities.)

Accumulated Deficit

The cumulative net losses of a company since its inception, less any net income. (Dynavax has a substantial accumulated deficit of $953.726 million as of September 30, 2025, indicating historical unprofitability.)

Year-Over-Year Comparison

Compared to the prior year's nine-month period, Dynavax has seen a significant shift from net income to a net loss, primarily due to a large loss on debt extinguishment ($82.095 million) and a bad debt expense ($10.970 million). However, on a quarterly basis, revenue growth remains strong, with total revenues up 17.06% and net income increasing by 53.05%, indicating robust operational performance in the third quarter of 2025 despite the year-to-date challenges.

Key Financial Figures

• $0.001 — ge on which registered: Common Stock, $0.001 par value DVAX Nasdaq Global Select Mar

Filing Documents

• dvax-20250930.htm (10-Q) — 1671KB
• dvax-20250930xex311.htm (EX-31.1) — 10KB
• dvax-20250930xex312.htm (EX-31.2) — 10KB
• dvax-20250930xex321.htm (EX-32.1) — 6KB
• dvax-20250930xex322.htm (EX-32.2) — 6KB
• 0001628280-25-049536.txt ( ) — 8560KB
• dvax-20250930.xsd (EX-101.SCH) — 58KB
• dvax-20250930_cal.xml (EX-101.CAL) — 89KB
• dvax-20250930_def.xml (EX-101.DEF) — 266KB
• dvax-20250930_lab.xml (EX-101.LAB) — 727KB
• dvax-20250930_pre.xml (EX-101.PRE) — 513KB
• dvax-20250930_htm.xml (XML) — 1266KB

FINANCIAL INFORMATION

PART I FINANCIAL INFORMATION Item 1.

Financial Statements (Unaudited)

Financial Statements (Unaudited) 4 Condensed Consolidated Balance Sheets as of September 30, 2025 and December 31, 2024 4 Condensed Consolidated Statements of Operations for the Three and Nine Months Ended September 30, 2025 and 2024 5 Condensed Consolidated Statements of Comprehensive Loss for the Three and Nine Months Ended September 30, 2025 and 2024 6 Condensed Consolidated Statements of Stockholders' Equity for the Three and Nine Months Ended September 30, 2025 and 2024 7 Condensed Consolidated Statements of Cash Flows for the Three and Nine Months Ended September 30, 2025 and 2024 8 Notes to Unaudited Condensed Consolidated Financial Statements 9 Item 2.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 27 Item 3.

Quantitative and Qualitative Disclosures about Market Risk

Quantitative and Qualitative Disclosures about Market Risk 37 Item 4.

Controls and Procedures

Controls and Procedures 37

OTHER INFORMATION

PART II OTHER INFORMATION Item 1.

Legal Proceedings

Legal Proceedings 39 Item 1A.

Risk Factors

Risk Factors 39 Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 73 Item 3. Defaults upon Senior Securities 73 Item 4. Mine Safety Disclosures 73 Item 5. Other Information 73 Item 6. Exhibits 74

SIGNATURES

SIGNATURES 75 2 Table of Contents

FORWARD-LOOKING STATEMENTS

FORWARD-LOOKING STATEMENTS This Quarterly Report on Form 10-Q contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are subject to a number of risks and uncertainties. All statements that are not historical facts are forward-looking statements, including statements about sales of HEPLISAV-B, our ability to successfully commercialize HEPLISAV-B, CpG 1018 adjuvant or any future product, our anticipated market opportunity and level of sales of HEPLISAV-B and CpG 1018 adjuvant, our ability to manufacture sufficient supply of HEPLISAV-B to meet future demand, our business, collaboration, distribution and regulatory strategy, our ability to successfully support the development, manufacture and commercialization of other vaccines containing our CpG 1018 adjuvant, including any current or potential vaccine or vaccine candidate that stems from any of our collaborations, our ability to manufacture sufficient supply of CpG 1018 adjuvant to meet potential future demand in connection with new vaccines, our ability to advance our other product candidates, such as our shingles, plague and pandemic influenza programs, and to otherwise develop and expand our clinical research pipeline, including our Lyme disease program, expected timing of Investigational New Drug filings, initiation and completion of clinical trials and expected timing for data readouts, our ability to meet regulatory requirements, including post-marketing obligations and commitments, uncertainty regarding our capital needs and future operating results and profitability, anticipated sources of funds, liquidity and cash needs (including our ability to collect on accounts receivables), anticipated future revenue, success of our strategic partnerships, including our license agreement with Vaxart, Inc., anticipated benefits of our capital allocation strategy in general, including our sha

FINANCIAL INFORMATION

PART I. FINANCIAL INFORMATION

FINANCIAL STATEMENTS

ITEM 1. FINANCIAL STATEMENTS Dynavax Technologies Corporation Condensed Consolidated Balance Sheets (In thousands, except per share amounts) September 30, 2025 December 31, 2024 (unaudited) (Note 1) Assets Current assets: Cash and cash equivalents $ 160,247 $ 95,883 Marketable securities available-for-sale 487,568 617,951 Accounts receivables, net of allowance for doubtful accounts of $ 0 and $ 12,313 at September 30, 2025 and December 31, 2024, respectively 72,359 45,281 Other receivables 962 1,625 Inventories 73,288 70,054 Prepaid expenses and other current assets 19,907 18,147 Total current assets 814,331 848,941 Property and equipment, net 45,855 39,001 Operating lease right-of-use assets 19,904 21,608 Goodwill 2,199 1,946 Other assets, net of allowance for doubtful accounts of $ 10,970 at September 30, 2025 64,217 74,760 Total assets $ 946,506 $ 986,256 Liabilities and stockholders' equity Current liabilities: Accounts payable $ 3,948 $ 9,061 Accrued research and development 6,697 4,310 Accrued liabilities 51,889 61,066 Convertible Notes, current portion, net of debt discount of $ 135 at September 30, 2025 (Note 7) 40,073 - Other current liabilities 4,232 4,197 Total current liabilities 106,839 78,634 Convertible Notes, net of debt discount of $ 4,034 and $ 1,646 at September 30, 2025 and December 31, 2024, respectively (Note 7) 220,966 223,854 Long-term portion of lease liabilities 23,985 26,388 CEPI accrual long-term (Note 6) 60,337 60,337 Other long-term liabilities 241 244 Total liabilities 412,368 389,457 Commitments and contingencies (Note 5) Stockholders' equity: Preferred stock: $ 0.001 par value, 5,000 shares authorized at September 30, 2025 and December 31, 2024; zero shares outstanding at September 30, 2025 and December 31, 2024 - - Common stock: $ 0.001 par value, 278,000 shares authorized at September 30, 2025 and December 31, 2024; 117,364 shares and 125,450 shares issued and outstanding at September 30

View Full Filing

View this 10-Q filing on SEC EDGAR